Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease

LiverMultiScan accurately identified patients with steatosis, stratified those with NASH, and reliably excluded clinically significant liver disease, with superior negative predictive value (83.3%) vs. transient elastography (42.9%) and ELF (57.1%). For NAFLD risk stratification, LiverMultiScan was cost-effective and, when combined with transient elastography, delivered the lowest cost per correct diagnosis.